Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook

benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported first-quarter 2025 sales of roughly $10.89 billion (78.09 billion Danish kroner), missing the consensus of $11.64 billion.
Sales increased by 19% in Danish kroner and 18% at CER. In U.S. Operations, sales increased by 20% in Danish kroner…

This story appeared on benzinga.com, 2025-05-07 13:09:44.
The Entire Business World on a Single Page. Free to Use →